Fortis Pharmaceuticals \u2014 the country\u2019s only GPP-certified personalized pharmacy, which has successfully prepared customized medications based on extemporaneous and officinal formulas for years \u2014 has become the official representative and strategic partner of global leader Fagron.<\/p>\n
This collaboration marks an important step toward elevating the local company\u2019s existing high standards to an entirely new level.<\/p>\n
“Strategic partnership with Fagron is a great recognition and an exciting opportunity for our team. For years, our efforts have been dedicated to compounding customized medications for patients, and this partnership enables us to provide Georgian patients with services backed by broader, world-class resources and standards,” notes Zurab Baratashvili, Director of Fortis Pharmaceuticals.<\/p>\n
With the support of Fagron, which operates in more than 30 countries worldwide, the Fortis Pharmaceuticals team has gained access to crucial and valuable resources. Specifically, the company will work with active pharmaceutical ingredients (APIs) and ready-to-use pharmaceutical bases manufactured at Fagron’s GMP-certified facility in the Netherlands.<\/p>\n
Notably, the innovative Fagron Formulary platform offers physicians and pharmacists over 10,000 verified compounding formulations and professional SOPs. In addition, Fagron Academy resources will unlock expanded avenues for professional development for the Georgian team.<\/p>\n
In Georgia, patients frequently face drug shortages, whether a product has been discontinued by the manufacturer or simply withdrawn from the local market. There are also cases where a patient requires a specific dosage or formulation that does not exist commercially.<\/p>\n
The partnership between Fagron and Fortis Pharmaceuticals provides an opportunity to advance modern compounding in Georgia to address this gap.<\/span><\/p>\n International expertise, pharmaceutical raw materials, technological know-how, and standardized formulations merge with local pharmaceutical infrastructure to prepare customized medications based on extemporaneous prescriptions tailored to specific clinical needs \u2014 strictly within the scope of physician orders and applicable regulations.<\/p>\n For Georgia, this means patient care will no longer depend solely on whether a specific finished drug product is commercially available on store shelves.<\/p>\n This collaboration creates a pharmaceutical ecosystem that grants physicians therapeutic freedom, provides pharmacists with advanced technical capabilities, and guarantees patients uninterrupted access to essential medications.<\/p>\n Through this alliance with Fortis Pharmaceuticals, Fagron\u2019s global experience and technological know-how will accelerate the development of advanced compounding and broaden personalized pharmacy capabilities across Georgian healthcare.<\/p>\n","protected":false},"excerpt":{"rendered":" Fortis Pharmaceuticals \u2014 the country\u2019s only GPP-certified personalized pharmacy, which has successfully prepared customized medications based on extemporaneous and officinal formulas for years \u2014 has become the official representative and strategic partner of global leader Fagron. This collaboration marks an important step toward elevating the local company\u2019s existing high standards to an entirely new level. […]<\/p>\n","protected":false},"author":2,"featured_media":25498,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1594],"tags":[7204,7203],"class_list":["post-25499","post","type-post","status-publish","format-standard","has-post-thumbnail","category-news","tag-fagron","tag-fortis-pharmaceuticals"],"acf":[],"_links":{"self":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/25499","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/comments?post=25499"}],"version-history":[{"count":1,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/25499\/revisions"}],"predecessor-version":[{"id":25503,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/posts\/25499\/revisions\/25503"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media\/25498"}],"wp:attachment":[{"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/media?parent=25499"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/categories?post=25499"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medscriptum.org\/en\/wp-json\/wp\/v2\/tags?post=25499"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}